Impact of Male Partner Involvement on Women’s Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial

被引:0
作者
Sarah T. Roberts
Gonasagrie Nair
Jared M. Baeten
Thesla Palanee-Philips
Katie Schwartz
Krishnaveni Reddy
Samuel Kabwigu
Flavia Matovu Kiweewa
Vaneshree Govender
Zakir Gaffoor
Nishanta Singh
Samantha Siva
Kalendri Naidoo
Elizabeth T. Montgomery
机构
[1] Women’s Global Health Imperative,Desmond Tutu HIV Research Centre
[2] RTI International,Departments of Global Health, Medicine, and Epidemiology
[3] University of Cape Town,HIV Prevention Research Unit (HPRU)
[4] University of Washington,undefined
[5] Wits Reproductive Health and HIV Institute (Wits RHI),undefined
[6] FHI 360,undefined
[7] Makerere University-Johns Hopkins University Research Collaboration,undefined
[8] Medical Research Council (MRC),undefined
[9] Centre for the AIDS Programme of Research in South Africa (CAPRISA),undefined
来源
AIDS and Behavior | 2020年 / 24卷
关键词
Microbicides; HIV prevention; Women; Male involvement; Gender; Dapivirine vaginal ring;
D O I
暂无
中图分类号
学科分类号
摘要
Although vaginal microbicides for HIV prevention are designed to be female-initiated, male partner influence has been identified as one of the most significant factors impacting women’s willingness and ability to use them. As a result, research teams have sought to increase male partner involvement by encouraging disclosure of product use to male partners, promoting male partner engagement in the study through attendance at the study clinic, and helping women to garner male partner support for product use. This paper aims to assess the impact of these three elements of male partner involvement on women’s adherence to the dapivirine vaginal ring during MTN-020/ASPIRE, a phase III randomized placebo-controlled clinical trial involving 2629 women in Malawi, South Africa, Uganda, and Zimbabwe. During the study, 64–80% of participants reported disclosure of ring use at each quarterly visit, and 13% reported that their partners had attended the study clinic at some point during the study. At study exit, 66% reported that their partner was supportive, 18% unsupportive, and 17% were unsure. After adjusting for age, site and time in study, women were more likely to have low ring adherence if they had an unsupportive male partner (aRR 1.29, 95% CI 1.03–1.62). Neither disclosure nor clinic attendance directly predicted ring adherence, but disclosure increased the probability of having a supportive partner (aRRR 24.17, 95% CI 16.38–35.66) or an unsupportive partner (aRRR 4.10, 95% CI 2.70–6.24), relative to an unknown level of partner support. Women were also more likely to have a supportive partner if their partner had attended the clinic (aRRR 3.77, 95% CI 1.36–10.42). This study suggests that although the vaginal ring is relatively discreet, lack of support from male partners remains a relevant barrier to use. Though both disclosure and clinic attendance may increase partner support, disclosure may also increase partner opposition. Interventions to reduce male partner opposition are needed to maximize the potential impact of the ring and other PrEP products for HIV prevention.
引用
收藏
页码:1432 / 1442
页数:10
相关论文
共 158 条
[91]  
Karim SS(undefined)undefined undefined undefined undefined-undefined
[92]  
Palanee-Phillips T(undefined)undefined undefined undefined undefined-undefined
[93]  
Roberts ST(undefined)undefined undefined undefined undefined-undefined
[94]  
Reddy K(undefined)undefined undefined undefined undefined-undefined
[95]  
Govender V(undefined)undefined undefined undefined undefined-undefined
[96]  
Naidoo L(undefined)undefined undefined undefined undefined-undefined
[97]  
Siva S(undefined)undefined undefined undefined undefined-undefined
[98]  
Gafos M(undefined)undefined undefined undefined undefined-undefined
[99]  
Pool R(undefined)undefined undefined undefined undefined-undefined
[100]  
Mzimela MA(undefined)undefined undefined undefined undefined-undefined